Current Report Filing (8-k)
March 20 2019 - 05:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2019
Portola Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35935
|
|
20-0216859
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
270 E. Grand Avenue
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650)
246-7300
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On March 15, 2019, Charles Homcy, M.D. notified Portola Pharmaceuticals, Inc.
(the Company) of his decision to resign as a member of the Board of Directors of the Company (the Board), effective upon execution of a consulting agreement. Dr. Homcy indicated that his decision to resign was not a
result of any disagreement with the Company on any matter relating to the Companys operations, policies or practices.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Portola Pharmaceuticals, Inc.
|
|
|
|
|
Dated: March 20, 2019
|
|
|
|
By:
|
|
/s/ John B. Moriarty, Jr.
|
|
|
|
|
|
|
John B. Moriarty, Jr.
|
|
|
|
|
|
|
Executive Vice President, General Counsel and Secretary
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Mar 2023 to Mar 2024